RAC 3.77% $1.53 race oncology ltd

General Comments / Chat, page-7516

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29638
    My current view is that the following ideally need to occur before there will be news via any of the major US or international biotech media channels:
    1. appointment of CMO,
    2. appointment of CSO,
    3. engagement of additional KoLs,
    4. potential update of Scientific Advisory Board (SaB),
    5. locking-in Product List,
    6. update of Clinical Development Plan (CDP),
    7. update of underlying Pipeline(s) for each Product,

    8. completion of draft/internal updates to Strategy,

    9. update of Outlook in Preliminary Annual Report,

    10. Strategy Updates prior to and via AGM

    11. Further releases of In-human data
    Of course in the meantime DCB and his team may be starting to engage with international media outlets and some international investors via their silent presence at international conferences.

    We haven’t seen any evidence of RACE exhibiting at any international conferences yet or coverage via international biotech media. I don’t think we will until most if not all the above have occurred. Of course in-human data could prompt earlier reporting by some of the more major biotech/pharma media channels many of us are following.

    Again, this is my current view and thoughts. My list is probably incomplete.
    Last edited by wombat777: 06/05/23
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.